FDA approves Rocklatan for open-angle glaucoma, ocular hypertension

The FDA has approved Rocklatan, a once-daily IOP-lowering eye drop, for patients with open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.

A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP, the release said.

FDA approval is based on data from two phase 3 trials in which Rocklatan demonstrated statistically significant IOP reduction compared with its two individual components.

Aerie plans to launch Rocklatan in the United States in the second quarter.

The FDA has approved Rocklatan, a once-daily IOP-lowering eye drop, for patients with open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.

A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP, the release said.

FDA approval is based on data from two phase 3 trials in which Rocklatan demonstrated statistically significant IOP reduction compared with its two individual components.

Aerie plans to launch Rocklatan in the United States in the second quarter.